Canaccord starts Niagen Bioscience at Buy on ‘unique opportunity’

Canaccord analyst Susan Anderson initiated coverage of Niagen Bioscience (NAGE) with a Buy rating and $13 price target Niagen, formerly known as ChromaDex, has evolved into a bioscience company centered around researching and commercializing nicotinamide adenine dinucleotide and other precursors to help with healthy aging, the analyst tells investors in a research note. The firm says that various studies have indicated that a decline in NAD+ levels leads to age-related disease and health conditions. This is where Niagen comes in as it offers products to help boost NAD+ levels, notes Canaccord. It believes Niagen offers a “unique opportunity to invest into a fast-growing consumer health care company with further growth upside.”